{"podcast":{"title":"The Readout Loud","slug":"the-readout-loud-1134305","podcast_index_feed_id":1134305,"rss_url":"https://feeds.megaphone.fm/thereadoutloud","website_url":"https://soundcloud.com/readout-loud","image_url":"https://megaphone.imgix.net/podcasts/2700b5c2-6d26-11ee-87eb-1f9099431c15/image/517bb4949d560305bb39448edbb32d7a.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress","author":"STAT","episode_count":414,"summary":"STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.","last_synced_at":"2026-07-17T08:20:19.054206+00:00","page_url":"https://stenobird.com/podcast/the-readout-loud-1134305"},"episode":{"title":"387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s","slug":"387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s","published_at":"2026-02-05T20:49:00+00:00","page_url":"https://stenobird.com/podcast/the-readout-loud-1134305/387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s","show_page_url":"https://stenobird.com/podcast/the-readout-loud-1134305","url":"https://traffic.megaphone.fm/TTSAA7740815504.mp3?updated=1770325297","audio_url":"https://traffic.megaphone.fm/TTSAA7740815504.mp3?updated=1770325297","summary":"On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a roadblock with the Trump White House, and a closer look at why manufacturing problems have slowed the rollout of a crucial sickle cell treatment. It’s our pre-Super Bowl show, which triggered some co-host squabbling. Adam Feuerstein is all Patriots, Elaine Chen is Team Seahawks, while Allison DeAngelis, raised in Seattle but now a Boston denizen, struggles with dual loyalties. Our special guest this week is STAT reporter Jason Mast. And if you get a chance, wish Adam a happy birthday.","meta_description":"On this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pat…","key_points":[],"chapters":[],"topics":[],"duration_seconds":1684,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-readout-loud-1134305/episodes/387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-readout-loud-1134305/387-challenges-for-a-crucial-sickle-cell-treatment-and-the-latest-outlook-for-glp-1s.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}